α-内收蛋白基因多态性与氢氯噻嗪降压疗效的相关性研究  

Association of polymorphism in α-adducin gene with antihypertensive effect of Hydrochlorothiazide

作　　者：吴寿岭[1] 李冬青[1] 李宏芬[1] 于青[1] 李云[1] 赵海燕[1] 

机构地区：[1]华北煤炭医学院附属开滦医院,唐山063000

出　　处：《中华心血管病杂志》2005年第10期880-884,共5页Chinese Journal of Cardiology

摘　　要：目的探讨原发性高血压患者α-内收蛋白基因多态性与氢氯噻嗪降压疗效的相关性。方法829例原发性高血压患者同时服用氢氯噻嗪12.5mg,每日1次,共6周,用PCR-RFLP方法检测α-内收蛋白基因第10外显子G614T单核苷酸多态性(SNP)。资料完整的754例原发性高血压患者按TT、GT、GG三种基因型分组,比较不同基因型患者的降压疗效。结果含T等位基因患者的Δ舒张压(DBP)、Δ平均动脉压(MAP)值大于GG基因型患者的ΔDBP、ΔMAP值,差异有统计学意义(P<0.05);TT基因型患者的Δ收缩压(SBP)、ΔMAP值大于GT、GG基因型患者的ΔSBP、ΔMAP值,差异有统计学意义(P<0.05);TT基因型患者的降压有效率高于GT、GG基因型患者的降压有效率,差异有统计学意义(P<0.05)。多元逐步回归分析显示TT基因型、治疗前SBP水平是影响收缩压下降值的主要因素。结论α-内收蛋白基因多态性与氢氯噻嗪的降压疗效相关,TT基因型患者的降压疗效最显著。Objective To explore the association between G614T single nuclear polymorphism （SNP） of the α-adducin gene and the antihypertensive effect of hydrochlorothiazide （HCTZ）in essential hypertensive （EH） patients. Methods Eight hundreds twenty nine EH patients were given 12. 5 mg HCTZ/d for six weeks,α-adducin gene G614T SNP in the tenth exon was determined by PCR-RFLP in 754 patients with complete records. All the patients were grouped according to TT, GT and GG genotypes. Results After 6 weeks of HCTZ treatment, the decreases in DBP and MAP of patients carrying 614T allele of α- adducin were significantly greater than that of those carrying GG homozygotes （P 〈 0. 05 ） . The decreases in SBP and MAP were significantly greater in patients with the TT genotype as compared with GT or GG genotype （ P 〈 0. 05 ）. The effective rate of BP fall by HCTZ was higher in patients with TT genotype than those with GT or GG genotype （ P 〈 0. 05 ）. Multivariate stepwise regression analysis showed that the TT genotype and the baseline SBP were the two major predictors affecting the decrease in SBP. Conclusion The present study suggests that the α-adducin G614T polymorphism is associated with the antihypertensive effect of HCTZ, which is more effective in patients with TF genotype.

关 键 词：高血压 基因 单核苷酸 多态性 利尿药 噻嗪 治疗结果 

分 类 号：R544.1[医药卫生—心血管疾病] R541.4[医药卫生—内科学]